Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PIKA rabies vaccine · 2 trials · 1 indication
Evaluation of the accelerated regimen is studied to check if the levels of anti-rabies antibodies (serum RVNA titer) will be better than a classic course with control commercialized vaccine.
Assessment of safety based on the identification of any adverse events for all the treatment groups, Group A, Group B and Group C through to the end of the study at day 42.
To analyze the titer level of RVNA from serum at day 14 and 42 after the first injection and with RVNA titer meeting the 0.5 IU(International units) /ml World Health Organization (WHO) requirement
| Arm | Type | Description |
|---|---|---|
| RABIPUR® | ACTIVE_COMPARATOR | Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14 |
| PIKA Rabies vaccine | EXPERIMENTAL | PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose) |
| Group A | ACTIVE_COMPARATOR | Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14 |
| Group B | EXPERIMENTAL | PIKA Rabies vaccine Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14 |
| Group C | EXPERIMENTAL | PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose) |
| Name | Type | Description |
|---|---|---|
| RABIPUR® | BIOLOGICAL | Biological rabies vaccine |
| PIKA rabies vaccine | BIOLOGICAL | Biological rabies vaccine |
| PIKA rabies vaccine with an accelerated regimen | BIOLOGICAL | Biological rabies vaccine |
Inclusion Criteria: * Informed consent form has been signed and dated * Able to attend all scheduled visits and comply with all trial procedures. * Never received rabies vaccine before. * Refrain from blood donation during the course of the study. * Able to attend all scheduled visits and comply wi...
The PIKA rabies vaccine is an investigational vaccine being developed for the prevention of rabies. It contains the PIKA adjuvant and is administered using an accelerated regimen. It is being developed by LakeShore Biopharma Co., Ltd and has been studied in two completed clinical trials in Singapore.
The PIKA rabies vaccine is being developed for the prevention of rabies. It is intended for use in healthy volunteers and is administered using an accelerated regimen. It is an investigational product and has not been approved for commercial use.
The PIKA rabies vaccine is being developed by LakeShore Biopharma Co., Ltd, which trades under the ticker LSB. The company has conducted clinical trials of the vaccine in Singapore.
The PIKA rabies vaccine is in Phase 2 clinical development. Two trials have been completed: a Phase 1 trial and a Phase 2 trial. It is an investigational vaccine and has not been approved by the FDA or any regulatory authority.
The PIKA rabies vaccine has been studied in two completed clinical trials. The Phase 2 trial, NCT02956421, enrolled 126 participants and evaluated efficacy and safety with an accelerated regimen. The Phase 1 trial, NCT02657161, enrolled 37 participants and assessed safety and efficacy. Both trials were conducted in Singapore.